211 related articles for article (PubMed ID: 25473899)
1. ZHX2 enhances the cytotoxicity of chemotherapeutic drugs in liver tumor cells by repressing MDR1 via interfering with NF-YA.
Ma H; Yue X; Gao L; Liang X; Yan W; Zhang Z; Shan H; Zhang H; Spear BT; Ma C
Oncotarget; 2015 Jan; 6(2):1049-63. PubMed ID: 25473899
[TBL] [Abstract][Full Text] [Related]
2. Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma.
Luan F; Liu P; Ma H; Yue X; Liu J; Gao L; Liang X; Ma C
Int J Biochem Cell Biol; 2014 Oct; 55():129-35. PubMed ID: 25195714
[TBL] [Abstract][Full Text] [Related]
3. ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation.
Lin Q; Wu Z; Yue X; Yu X; Wang Z; Song X; Xu L; He Y; Ge Y; Tan S; Wang T; Song H; Yuan D; Gong Y; Gao L; Liang X; Ma C
EBioMedicine; 2020 Mar; 53():102676. PubMed ID: 32114388
[TBL] [Abstract][Full Text] [Related]
4. ZHX2 is a repressor of alpha-fetoprotein expression in human hepatoma cell lines.
Shen H; Luan F; Liu H; Gao L; Liang X; Zhang L; Sun W; Ma C
J Cell Mol Med; 2008 Dec; 12(6B):2772-80. PubMed ID: 18194454
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of a novel gene, ZHX2, in hepatocellular carcinoma.
Lv Z; Zhang M; Bi J; Xu F; Hu S; Wen J
Am J Clin Pathol; 2006 May; 125(5):740-6. PubMed ID: 16707376
[TBL] [Abstract][Full Text] [Related]
6. Zinc fingers and homeoboxes 2 inhibits hepatocellular carcinoma cell proliferation and represses expression of Cyclins A and E.
Yue X; Zhang Z; Liang X; Gao L; Zhang X; Zhao D; Liu X; Ma H; Guo M; Spear BT; Gong Y; Ma C
Gastroenterology; 2012 Jun; 142(7):1559-70.e2. PubMed ID: 22406477
[TBL] [Abstract][Full Text] [Related]
7. ZHX2 inhibits SREBP1c-mediated de novo lipogenesis in hepatocellular carcinoma via miR-24-3p.
Yu X; Lin Q; Wu Z; Zhang Y; Wang T; Zhao S; Song X; Chen C; Wang Z; Xu L; Li C; Gao L; Liang X; Yue X; Ma C
J Pathol; 2020 Dec; 252(4):358-370. PubMed ID: 32770671
[TBL] [Abstract][Full Text] [Related]
8. HBV suppresses ZHX2 expression to promote proliferation of HCC through miR-155 activation.
Song X; Tan S; Wu Z; Xu L; Wang Z; Xu Y; Wang T; Gao C; Gong Y; Liang X; Gao L; Spear BT; Ma C
Int J Cancer; 2018 Dec; 143(12):3120-3130. PubMed ID: 29752719
[TBL] [Abstract][Full Text] [Related]
9. [The methylation of ZHX2 gene promoter enhances AFP gene expression in hepatocellular carcinoma].
Lv Z; DU Y; Wen J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jul; 29(7):706-9. PubMed ID: 23837980
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor ZHX2 inhibits NAFLD-HCC progression via blocking LPL-mediated lipid uptake.
Wu Z; Ma H; Wang L; Song X; Zhang J; Liu W; Ge Y; Sun Y; Yu X; Wang Z; Wang J; Zhang Y; Li C; Li N; Gao L; Liang X; Yue X; Ma C
Cell Death Differ; 2020 May; 27(5):1693-1708. PubMed ID: 31740790
[TBL] [Abstract][Full Text] [Related]
11. Kanglaite enhances the efficacy of cisplatin in suppression of hepatocellular carcinoma via inhibiting CKLF1 mediated NF-κB pathway and regulating transporter mediated drug efflux.
Chen C; Ai QD; Wei YH
J Ethnopharmacol; 2021 Jan; 264():113388. PubMed ID: 32918990
[TBL] [Abstract][Full Text] [Related]
12. Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.
Zhuang Q; Zhou T; He C; Zhang S; Qiu Y; Luo B; Zhao R; Liu H; Lin Y; Lin Z
J Exp Clin Cancer Res; 2016 Apr; 35():67. PubMed ID: 27074866
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma.
Park SY; Han J; Kim JB; Yang MG; Kim YJ; Lim HJ; An SY; Kim JH
Eur J Cancer; 2014 Jan; 50(2):341-50. PubMed ID: 24161763
[TBL] [Abstract][Full Text] [Related]
14. Targeting genes and signaling pathways of transcriptional suppressor ZHX2 in hepatocellular carcinoma: a Chromatin Immunoprecipitation-sequencing (ChIP-seq) investigation.
Lv Z; He R; Huang M; Zhao G; Ma J; Chen G
Neoplasma; 2019 May; 66(3):437-445. PubMed ID: 30784286
[TBL] [Abstract][Full Text] [Related]
15. Construction of a recombinant eukaryotic human ZHX1 gene expression plasmid and the role of ZHX1 in hepatocellular carcinoma.
Wang J; Liu D; Liang X; Gao L; Yue X; Yang Y; Ma C; Liu J
Mol Med Rep; 2013 Nov; 8(5):1531-6. PubMed ID: 24064680
[TBL] [Abstract][Full Text] [Related]
16. Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-kappaB and NF-Y activation in oral carcinoma cells.
Shareef MM; Brown B; Shajahan S; Sathishkumar S; Arnold SM; Mohiuddin M; Ahmed MM; Spring PM
Mol Cancer Res; 2008 Jan; 6(1):89-98. PubMed ID: 18234965
[TBL] [Abstract][Full Text] [Related]
17. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
[TBL] [Abstract][Full Text] [Related]
18. BCAT1, a key prognostic predictor of hepatocellular carcinoma, promotes cell proliferation and induces chemoresistance to cisplatin.
Zheng YH; Hu WJ; Chen BC; Grahn TH; Zhao YR; Bao HL; Zhu YF; Zhang QY
Liver Int; 2016 Dec; 36(12):1836-1847. PubMed ID: 27246112
[TBL] [Abstract][Full Text] [Related]
19. Expression of zinc-fingers and homeoboxes 2 in hepatocellular carcinogenesis: a tissue microarray and clinicopathological analysis.
Hu S; Zhang M; Lv Z; Bi J; Dong Y; Wen J
Neoplasma; 2007; 54(3):207-11. PubMed ID: 17447851
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
